Amarna Therapeutics and NorthX Biologics partner to advance Nimvec

Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner.

Amarna says this partnership represents a major step in advancing the clinical trial manufacturing of Nimvec AM510, Amarna’s ground-breaking gene therapy platform designed to transform the treatment of immune-mediated diseases. The collaboration will begin with the transfer of Amarna’s research-scale production process for Nimvec AM510 to NorthX Biologics. No financial terms of the collaboration were disclosed.

The company's proprietary Nimvec platform is designed to deliver transformative treatments with exceptional promise in pre-clinical studies. Amarna is committed to pioneering treatments for type 1 diabetes mellitus and enhancing patient outcomes.